Minneapolis-based U.S. Bancorp (USB) reported Q2 profit that beat analysts estimate. Revenue, however, didn’t meet the consensus estimate. During the quarter, the company reported earnings of $1.02 a share, topping analysts’ estimate of $1.00. Revenue came in at $5.64 billion.
The increase in net income on a year-over-year basis was primarily due to total net revenue growth of 3.5%. Net interest income increased 4.9%, mainly as a result of the impact of rising interest rates and earning assets growth.
Early this year, the American lender was fined $613 million due to poor money laundering controls. According to the U.S. Justice Department, the company deliberately ran inappropriate an anti-money-laundering program from 2009 to 2014, through its subsidiary U.S. Bank National Association. According to Reuters, if the bank meets the terms of the agreement, the charges against it would be dismissed.
The company’s board also approved an increase in the quarterly dividend to $0.37 per share beginning in the third quarter of 2018, as well as a new share repurchase program for the year.
Related: Morgan Stanley shares surge after Q2 earnings beat
Along with U.S. Bancorp, Morgan Stanley (MS) too reported its earnings today, concluding the earnings for major US banks. Morgan Stanley smashed past analysts’ expectations during Q2 2018, aided by strong performance in investment banking and trading. The bank reported earnings of $1.30 per share, topping analysts’ expectation of $1.08. Revenue during the quarter rose to $10.6 billion, topping the consensus estimate of $10.5 billion.
Related: U.S. Bancorp Q2 2018 earnings call transcript
Despite the earnings beat, shares of U.S. Bancorp dropped 1% during the first hour of trading session today. The stock was trading between $58.50 and $48.49 during the past 52-week period.
Related: Goldman Sachs tops estimates; profit jumps 44%
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on